Document:

EX-10.15

 Exhibit 10.15 

May 26, 2014 
 Ms. Kate Falberg 

 

	Re:	Board of Directors Offer Letter 

 Dear Kate: 

On behalf of aTyr Pharma, Inc. (the “Company”), I am pleased to invite you to serve on the Company’s Board of
Directors (the “Board”), with an effective start dale of June 1, 2014 (the “Start Date”). We believe that you will be able to make an important contribution to our efforts to bring meaningful medicines to
patients in grave need. 
 Subject to your appointment to the Board and to Board approval, you will be granted a non-qualified
option to purchase 100,000 shares of the Company’s common stock under the Company’s 2012 Stock Plan (as amended from time to time, the “Plan”) at an exercise price per share equal to the fair market value of one share of
the Company’s common stock on the date of the grant (the “Option”) as determined by the Board. The Option will be subject to the terms and conditions of the Plan and the standard stock option agreement provided pursuant to the
Plan, which you will be required to sign as a condition of receiving the Option. Subject to your acceptance of this offer and your continued service on the Board, the Option will vest in equal monthly installments over a thirty-six (36) month
period from and after the Start Date; provided, that all then-unvested shares subject to the Option shall immediately vest and become exercisable immediately prior to. but contingent upon, the consummation of a Change in Control (as defined in the
Plan). The Company shall (i) until otherwise determined by the Board, pay you (a) a fee of $20,000.00 per annum to serve as a member of the Board, with such amount to be paid in equal installments of $5,000.00 on a quarterly basis and
(b) a fee of $25,000.00 per annum to serve as the Chairperson of the Audit Committee of the Board, with such amount to be paid in equal installments of $6,250.00 on a quarterly basis, (ii) provide you with the opportunity to become a party
to the Company’s form of Indemnification Agreement for executive officers and directors, and (iii) reimburse reasonable out-of-pocket expenses incurred by you in connection with your service on the Board and related activities, following
receipt of acceptable documentation of such expenses and in accordance with the Company’s policies. 
 As a member of the Board,
the Company anticipates that you will attend Board meetings in person or by phone, which the Company anticipates will be held on a quarterly basis, as well as periodic 

 
update Board teleconferences, and will provide guidance on a periodic basis to the CEO and the leant on issues of strategic and operational importance. Your name and bio will also appear on our
website and materials in the Board of Directors section. Your service as a member of the Board will be subject to fiduciary duties as provided for under applicable law. such as the duties of care and loyally (including an obligation to maintain the
confidentiality of the Company’s proprietary and confidential information that will be provided to you in the course of your serving as a member of the Board, and by signing below, you acknowledge and agree to comply with such duties and
obligations). 
 On behalf of all of the Company’s management and the other Directors, we are excited about you joining the Board and
look forward to your input and guidance. 
  

	
	Sincerely,
	
	/s/ John D. Mendlein, Ph.D.
	
	 John D. Mendlein, Ph.D.
 Executive Chairman and
CEO

	
	AGREED TO AND ACCEPTED:
	
	 /s/ Kate Falberg

	(Signature)EX-10.16

 Exhibit 10.16 

aTyr Pharma 
  

April 21, 2015 
 Mark Goldberg 

 

	Re:	aTyr Pharma, Inc. Board of Directors 

 Dear Mark: 

On behalf of aTyr Pharma, Inc. (the “Company”), we would like to extend the invitation to you to join the Company’s Board of Directors
(the “Board”). Once you accept this invitation, we anticipate the Board moving quickly to formally appoint you as a member of the Board. 

As you are aware, the Company is a Delaware corporation and, therefore, your rights and duties as a Board member are prescribed by Delaware law and our
charter documents, as well as by the policies established by our Board from time to time. Upon the completion of the Company’s proposed initial public offering, the Company will also be subject to the rules and regulations of the U.S.
Securities and Exchange Commission (the “SEC”) and the NASDAQ Stock Exchange (“NASDAQ”). In addition, please note that, as a director, you will be subject to the corporate policies that the Company will adopt,
including the Company’s Code of Business Conduct, Communication Policy and Insider Trading Policy. 
 The Board will establish three standing
committees – the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee, and from time to time, the Board may establish additional committees to which it may delegate certain duties. As a member of the
Board, you may be asked to serve on one or more of such committees. In addition to committee meetings, which shall be convened as needed, our Board meetings are generally held at least quarterly at the Company’s headquarters, and you would be
expected to attend these meetings, as well as any special meetings that may be scheduled from time to time. 
 You agree that you will hold in strictest
confidence, and not use, except for the benefit of the Company, or disclose to any person, firm, corporation or other entity, without written authorization of the Board, any non-public, confidential or proprietary information of the Company, except
to the extent that such disclosure or use may be required in direct connection with your duties as a member of the Board. It is expected that during the term of your Board membership you will not engage in any other employment, occupation,
consulting or other business activity that competes with the business in which the Company is now involved in or becomes involved in during the term of your service on the Board, nor will you engage in any other activities that conflict with your
obligations to the Company. 
  
  

			
	 		3545 John Hopkins Court
			Suite #250
			San Diego, CA 92121
			858.731.8389 Phone
	Brave Science		858.731.9384 Fax
	Meaningful Medicines		www.atyrpharma.com

 Mark Goldberg, M.D. 

April 21, 2015 
 Page Two 

 

 As a non-employee director of the Board, you would be entitled to receive an initial grant of a non-qualified
stock option to purchase 100,000 shares of the Company’s Common Stock, par value $0.001 per share (“Common Stock”), pursuant to the terms of the Company’s 2014 Stock Plan (as amended, the “Plan”), at an
exercise price per share equal to the fair market value of the Common Stock on the date of the grant, as determined by the Board (the “Option”). The Option will be subject to the terms and conditions of the Plan and the standard
stock option agreement provided pursuant to the Plan, which you will be required to sign as a condition of receiving the Option. Subject to your acceptance of this offer and your continued service on the Board, the Option will vest in thirty-six
(36) equal monthly installments from date on which you are first appointed as a member of the Board; provided that the Option shall be exercisable immediately, regardless of whether such shares have vested at the time of exercise, subject to
the Company’s retention of the right to purchase any unvested shares, at the original purchase price paid by you upon exercise, following the termination of the your Service (as defined in the Plan). 

In addition to the initial Option grant, as a non-employee director of the Board, you would thereafter be entitled to receive the cash and equity compensation
for your service set forth in the Company’s Board of Directors Compensation Plan, as it may amended from time to time (the “Director Compensation Policy”). The Director Compensation Policy is expected to be replaced in the near
future in connection with the completion of the Company’s proposed initial public offering, and as such will provide for reimbursement of reasonable, customary and documented travel expenses to Board meetings as well as additional compensation
for service on the Board and its committees. 
 The payment of compensation to Board members is subject to many restrictions under applicable law, and as
such, you should be aware that the compensation set forth in the Director Compensation Policy is subject to such future changes and modifications as the Board, or its appropriate committees, may deem necessary or appropriate. In addition, please
note that unless otherwise approved by our Board or required under applicable law, directors of our subsidiaries shall not be entitled to any compensation. 

Please note that nothing in this letter or any agreement granting you equity incentive awards under any Company stock option or incentive plan should be
construed to interfere with or otherwise restrict in any way the rights of the Company, its Board or stockholders from removing you from the Board or any committee in accordance with the provisions of applicable law. Furthermore, except as otherwise
provided to other non-employee Board members or required by law, the Company does not intend to afford you any rights as an employee, including without limitation, the right to further employment or any other benefits. 

We hope that you find the foregoing terms acceptable. You may indicate your agreement with these terms by signing and dating both the enclosed duplicate and
original letter and returning them to me. By signing this letter you also represent that the execution and delivery of this agreement and the fulfillment of the terms hereof will not require the consent of another person, constitute a default under
or conflict with any agreement or other instrument to which you are 

  
 Brave Science 

Meaningful Medicines 

 Mark Goldberg, M.D. 

April 21, 2015 
 Page Three 

 

 
bound or a party. In addition, we will need you to complete, sign and deliver a standard director questionnaire. 

We look forward to you joining the Board. We anticipate your leadership and experience will make a key contribution to our success at this critical time and
going forward as we develop meaningful medicines for patients in grave need. 
 Sincerely, 

/s/ John D. Mendlein 
 John D. Mendlein, Ph.D. 

Chief Executive Officer and Executive Chairman 
  

 
  

			
	Acknowledged and Accepted:		
		
	 /s/ Mark Goldberg
		
	Mark Goldberg, M.D.		

  
 Brave Science 

Meaningful Medicines

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]